The medical applications of Newsight’s spectral technology are cutting edge and are best displayed through the company’s diagnostics kit – SpectraLIT™️. SpectraLIT™️, is based on Newsight’s spectrometer-on-chip technology, empowered by AI, all while being clinic-level accurate. Using light absorbance, it enables the detection of spectral profiles in a range of 400 to 1000nm . Newsight was successfully able to identify the presence of tropical viruses in pre-clinical test with almost 99% classification and prediction success, and now expending its research to the Coronavirus.
SpectraLIT™ is Newsight’s evaluation kit for the NSP2020, its Spectrometer on Chip. It detects light intensity in wavelengths that range continuously between 400nm and 700nm and provides 1024 digital values with up-to 12bit digital levels. These 1024 digital values allow the creation of a high-resolution spectral signature of any tested substance. The development kit has an IoT interface allowing for updates in case of viral mutation, consistently improves accuracy through AI, and can be developed to detect other microbials.
Virusight Diagnostic is a joint venture between Newsight Imaging and a ARC innovation center at Sheba Medical Center, the largest hospital in Israel and the Middle East, recognized by Newsweek magazine as one of the Top 10 Hospitals in the World. Virusight is developing revolutionary rapid-testing solutions based on Spectral technology and AI. The complete solution is a digital healthcare platform that enables immediate qualitative detection of various pathogens, including SARS-Cov-2.
Recent major clinical study of over 550 samples delivered 96.3% overall accuracy with 92.7% Sensitivity and 96.8% Specificity compared with an RT-PCR. The Virusight solution was found to be safe, accurate and effective at detecting SARS-CoV-2 antigens and viral particles in the samples, diagnosing COVID-19 in less than 20 seconds.
The world’s fastest COVID-19 test